Dang Shen is an East Asian tonic root herb used to support cellular energy, antioxidant defenses, immunity, and respiratory vitality. Human trials show multi-herb oral formulations and intravenous extracts improve lung function, muscle strength, memory, and chemotherapy tolerance, but none test standalone oral Dang Shen. Animal and cell findings show prostate hormone-receptor stimulation, slowed blood clotting, liver enzyme inhibition, and contamination risks, favoring verified sulfur-free extracts. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting Blood Pressure (SBP / DBP) | No established target; track change from individual baseline | Expected to change (efficacy) & safety check; measured seated in the morning after 5 minutes of rest |
| High-Sensitivity C-Reactive Protein (hs-CRP) | 0.0–3.0 mg/L (standard reference range) | Expected to change (efficacy); drawn fasting in the absence of acute infection |
| Fasting Blood Glucose (FBG) | 70–99 mg/dL (standard reference range) | Expected to change (efficacy); 8–12 hour overnight fast required |
| Complete Blood Count (CBC) with Differential | WBC 4.5–11.0 × 109/L; Platelets 150–400 × 109/L (standard reference range) | Expected to change (efficacy) & safety check; tracks leukocyte/lymphocyte support and screens for rare thrombocytopenia |
| Liver Transaminases (ALT, AST) | ALT 7–56 U/L; AST 8–33 U/L (standard reference range) | Safety check; screens for herbal adulterant or pesticide hepatotoxicity (trial exclusion > 2.5× ULN) |
| Coagulation Panel (PT / INR) | INR 0.8–1.1 (standard reference range) | Safety check; monitors for prolonged clotting time from platelet/coagulation inhibition, especially with antithrombotics |
| Total Prostate-Specific Antigen (PSA) | 0.0–4.0 ng/mL (standard reference range) | Safety check; monitored in men over 40 due to preclinical androgen receptor upregulation (drawn after 48 hours without ejaculation) |
Cadence: Baseline assessment (laboratory panel, seated morning blood pressure, and handgrip dynamometry) before initiation; safety blood tests (ALT, AST, CBC, and PT/INR) repeated at 4 weeks after initiation; all efficacy and safety biomarkers re-evaluated at 12 weeks and every 6 months thereafter during cyclical supplementation.